Last reviewed · How we verify
DaxibotulinumtoxinA 20 units
At a glance
| Generic name | DaxibotulinumtoxinA 20 units |
|---|---|
| Also known as | Daxxify |
| Sponsor | Main Line Center for Laser Surgery |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- DaxibotulinumtoxinA for Blepharospasm (PHASE2)
- Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A (PHASE4)
- Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial (NA)
- The Combined Effect of Intravesical Botox Injections and HoLEP Surgery in Treating Benign Prostatic Hyperplasia and Overactive Bladder (PHASE4)
- Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines (PHASE3)
- EMG-Based Evaluation of Occlusal Splint and Masseter Botox Effects on Head and Neck Muscles (PHASE4)
- A Study Comparing the Safety, Efficacy, and Diffusion of Letibotulinum Toxin A Versus Other Botulinum Toxin Products in Adults With Moderate-to-Severe Forehead Wrinkles (PHASE4)
- Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DaxibotulinumtoxinA 20 units CI brief — competitive landscape report
- DaxibotulinumtoxinA 20 units updates RSS · CI watch RSS
- Main Line Center for Laser Surgery portfolio CI